| Communication between multiple drug binding sites on P-glycoprotein C Martin, G Berridge, CF Higgins, P Mistry, P Charlton, R Callaghan Molecular pharmacology 58 (3), 624-632, 2000 | 557 | 2000 |
| Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis MF Rosenberg, R Callaghan, RC Ford, CF Higgins Journal of Biological Chemistry 272 (16), 10685-10694, 1997 | 529 | 1997 |
| Basis for design and development of platinum (IV) anticancer complexes MD Hall, HR Mellor, R Callaghan, TW Hambley Journal of medicinal chemistry 50 (15), 3403-3411, 2007 | 512 | 2007 |
| Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? R Callaghan, F Luk, M Bebawy Drug Metabolism and Disposition 42 (4), 623-631, 2014 | 450 | 2014 |
| Repacking of the transmembrane domains of P‐glycoprotein during the transport ATPase cycle MF Rosenberg, G Velarde, RC Ford, C Martin, G Berridge, ID Kerr, ... The EMBO journal, 2001 | 381 | 2001 |
| The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein C Martin, G Berridge, P Mistry, C Higgins, P Charlton, R Callaghan British journal of pharmacology 128 (2), 403-411, 1999 | 333 | 1999 |
| Collateral sensitivity as a strategy against cancer multidrug resistance KM Pluchino, MD Hall, AS Goldsborough, R Callaghan, MM Gottesman Drug Resistance Updates 15 (1-2), 98-105, 2012 | 332 | 2012 |
| A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene HW van Veen, R Callaghan, L Soceneantu, A Sardini, WN Konings, ... Nature 391 (6664), 291-295, 1998 | 314 | 1998 |
| Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer S Modok, HR Mellor, R Callaghan Current opinion in pharmacology 6 (4), 350-354, 2006 | 306 | 2006 |
| Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding MF Rosenberg, AB Kamis, R Callaghan, CF Higgins, RC Ford Journal of Biological Chemistry 278 (10), 8294-8299, 2003 | 303 | 2003 |
| Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state MF Rosenberg, R Callaghan, S Modok, CF Higgins, RC Ford Journal of Biological Chemistry 280 (4), 2857-2862, 2005 | 263 | 2005 |
| Resistance to chemotherapy in cancer: a complex and integrated cellular response HR Mellor, R Callaghan Pharmacology 81 (4), 275-300, 2008 | 208 | 2008 |
| Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells R Callaghan, JR Riordan Journal of Biological Chemistry 268 (21), 16059-16064, 1993 | 195 | 1993 |
| How can we best use structural information on P-glycoprotein to design inhibitors? CA McDevitt, R Callaghan Pharmacology & therapeutics 113 (2), 429-441, 2007 | 184 | 2007 |
| Structure of the multidrug resistance P-glycoprotein CF Higgins, R Callaghan, KJ Linton, MF Rosenberg, RC Ford Seminars in cancer biology 8 (3), 135-142, 1997 | 183 | 1997 |
| Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2 CA McDevitt, RF Collins, M Conway, S Modok, J Storm, ID Kerr, RC Ford, ... Structure 14 (11), 1623-1632, 2006 | 177 | 2006 |
| P‐glycoprotein: so many ways to turn it on R Callaghan, E Crowley, S Potter, ID Kerr The Journal of Clinical Pharmacology 48 (3), 365-378, 2008 | 160 | 2008 |
| The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence A Rothnie, D Theron, L Soceneantu, C Martin, M Traikia, G Berridge, ... European Biophysics Journal 30, 430-442, 2001 | 158 | 2001 |
| Interaction of tamoxifen with the multidrug resistance P-glycoprotein R Callaghan, CF Higgins British journal of cancer 71 (2), 294-299, 1995 | 158 | 1995 |
| Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy J Walker, C Martin, R Callaghan European journal of cancer 40 (4), 594-605, 2004 | 154 | 2004 |
